KR100290112B1 - 신규한 벤즈아미드 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물 - Google Patents

신규한 벤즈아미드 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR100290112B1
KR100290112B1 KR1019940007553A KR19940007553A KR100290112B1 KR 100290112 B1 KR100290112 B1 KR 100290112B1 KR 1019940007553 A KR1019940007553 A KR 1019940007553A KR 19940007553 A KR19940007553 A KR 19940007553A KR 100290112 B1 KR100290112 B1 KR 100290112B1
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
tetrahydro
benzoylamino
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940007553A
Other languages
English (en)
Korean (ko)
Inventor
히로유키 세토이
다케히코 오카와
다추야 젠코
게이지 헤미
히로카즈 다나카
Original Assignee
후지야마 아키라
후지사와 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지야마 아키라, 후지사와 야꾸힝 고교 가부시키가이샤 filed Critical 후지야마 아키라
Application granted granted Critical
Publication of KR100290112B1 publication Critical patent/KR100290112B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1019940007553A 1993-04-13 1994-04-11 신규한 벤즈아미드 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물 Expired - Fee Related KR100290112B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9307527.3 1993-04-13
GB939307527A GB9307527D0 (en) 1993-04-13 1993-04-13 New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
KR100290112B1 true KR100290112B1 (ko) 2001-05-15

Family

ID=10733683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940007553A Expired - Fee Related KR100290112B1 (ko) 1993-04-13 1994-04-11 신규한 벤즈아미드 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (17)

Country Link
US (1) US5521170A (enExample)
EP (1) EP0620216B1 (enExample)
JP (1) JPH072800A (enExample)
KR (1) KR100290112B1 (enExample)
CN (1) CN1058710C (enExample)
AT (1) ATE230729T1 (enExample)
AU (1) AU679719B2 (enExample)
CA (1) CA2121112A1 (enExample)
DE (1) DE69431974T2 (enExample)
DK (1) DK0620216T3 (enExample)
ES (1) ES2185635T3 (enExample)
GB (1) GB9307527D0 (enExample)
HU (1) HUT70197A (enExample)
IL (1) IL109228A0 (enExample)
PH (1) PH30793A (enExample)
TW (1) TW260667B (enExample)
ZA (1) ZA942325B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408185D0 (en) 1994-04-25 1994-06-15 Fujisawa Pharmaceutical Co New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DE69535486T2 (de) * 1994-06-15 2008-04-10 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclische Verbindungen verwendbar als Vasopressin- oder Oxytocin-Modulatoren
US5532235A (en) * 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5696112A (en) * 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
AR002459A1 (es) * 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5700796A (en) * 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9508637D0 (en) * 1995-04-28 1995-06-14 Fujisawa Pharmaceutical Co New use
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
AUPP150098A0 (en) * 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
EP2062583B1 (en) 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6765004B1 (en) * 1999-06-17 2004-07-20 Ortho-Mcneil Pharmaceutical, Inc. Indoloazepines as vasopressin receptor antagonists
JP2003503405A (ja) * 1999-06-28 2003-01-28 藤沢薬品工業株式会社 ベンズアミド誘導体
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
CN1440281A (zh) * 2000-05-03 2003-09-03 苏坎波公司 降眼压药
ES2288899T3 (es) * 2000-10-04 2008-02-01 Astellas Pharma Inc. Uso de un antagonista de vasopresina tal como conivaptan en la fabricacion de un medicamento para el tratamiento de la hipertension pulmonar.
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2293721C2 (ru) * 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP3988832B2 (ja) * 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
WO2006074358A1 (en) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
SI2261215T1 (sl) * 2005-09-02 2015-02-27 Otsuka Pharmaceutical Co., Ltd. Postopek priprave spojin benzazepina ali njihovih soli
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
JP4108729B2 (ja) * 2006-05-26 2008-06-25 日本たばこ産業株式会社 窒素含有縮合環化合物含有医薬組成物
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
AR064625A1 (es) 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
JP5383513B2 (ja) 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
WO2009036175A2 (en) 2007-09-14 2009-03-19 The Regents Of The University Of Michigan F1f0-atpase inhibitors and related methods
RU2010122902A (ru) 2007-11-06 2011-12-20 Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) Бензодиапениноновые соединения, применимые в лечении кожных состояний
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
EP2352724B1 (en) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryl guanidine f1f0-atpase inhibitors and their medical use
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
RU2011151399A (ru) * 2009-06-03 2013-07-20 Санофи-Авентис Дойчланд Гмбх Кристаллические фазы (2-пиридин-3-илэтил)амида 2'-{[2-(4-метоксифенил)ацетиламино]метил}бифенил-2-карбоновой кислоты
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
CN102812011A (zh) * 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
FR2969605A1 (fr) * 2010-12-28 2012-06-29 Univ Strasbourg Derives de 2,3,4,5-tetrahydro-1h-benzo[b]azepine et leur utilisation
TW201247627A (en) * 2011-04-28 2012-12-01 Bristol Myers Squibb Co Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
NZ720004A (en) 2013-11-18 2020-03-27 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors
CN117658868B (zh) * 2022-09-06 2025-12-19 中山大学 一种苯甲酰胺类衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005549A1 (en) * 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
CA2066104C (en) * 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
JPH05320135A (ja) * 1992-05-19 1993-12-03 Yamanouchi Pharmaceut Co Ltd テトラヒドロベンズアゼピン誘導体
TW249201B (enExample) * 1992-07-02 1995-06-11 Otsuka Pharma Co Ltd
JPH06157480A (ja) * 1992-11-30 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なベンズアニリド誘導体
AU6219994A (en) * 1993-03-11 1994-09-26 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005549A1 (en) * 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds

Also Published As

Publication number Publication date
AU5932294A (en) 1994-10-20
HUT70197A (en) 1995-09-28
DE69431974T2 (de) 2003-05-22
CN1098406A (zh) 1995-02-08
ATE230729T1 (de) 2003-01-15
DE69431974D1 (de) 2003-02-13
ES2185635T3 (es) 2003-05-01
HU9401041D0 (en) 1994-08-29
GB9307527D0 (en) 1993-06-02
US5521170A (en) 1996-05-28
CA2121112A1 (en) 1994-10-14
DK0620216T3 (da) 2003-05-05
PH30793A (en) 1997-10-17
JPH072800A (ja) 1995-01-06
EP0620216B1 (en) 2003-01-08
CN1058710C (zh) 2000-11-22
EP0620216A1 (en) 1994-10-19
IL109228A0 (en) 1994-07-31
AU679719B2 (en) 1997-07-10
TW260667B (enExample) 1995-10-21
ZA942325B (en) 1995-02-16

Similar Documents

Publication Publication Date Title
KR100290112B1 (ko) 신규한 벤즈아미드 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물
EP1296982B1 (en) 1-(heteroaryl-phenyl)-condensed pyrazol derivatives as factor xa inhibitors
EP0691960B1 (en) Antipsychotic benzimidazole derivatives
AP542A (en) Bicyclic Fibrinogen antagonists
US6716841B2 (en) Nitrogen containing heterobicycles as factor Xa inhibitors
NZ259802A (en) Bicyclic derivatives and pharmaceutical compositions
AU2005272738A1 (en) Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CA2129214A1 (en) 1-benzenesulfonyl-1,3-dihydro-2h-benzimidazol-2-one derivatives
CN104066724A (zh) P2x4受体拮抗剂
US20050090496A1 (en) Sulphonyl compounds with 5-ht6 receptor affinity
JP2002536359A (ja) インドール誘導体およびｍｃｐ−１拮抗物質としての該化合物の使用
HUP0104280A2 (hu) Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok, eljárás az előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények
EP0689539A1 (en) Antipsychotic indazole derivatives
US6495542B1 (en) Benzamide derivatives as vasopressin antagonists
Hussenether et al. Clozapine derived 2, 3-dihydro-1H-1, 4-and 1, 5-benzodiazepines with D4 receptor selectivity: synthesis and biological testing
JPH0873439A (ja) １−ベンジル−１，３−ジヒドロ−２ｈ−ベンズイミダゾール−２−オン誘導体、これらの調製およびこれらを含有する薬学的組成物
AU2009227111A1 (en) Novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof.
ES2223628T3 (es) Derivados de 4-fenil-1-piperazinilo, -piperidinilo y -tetrahidropiridilo.
HU193010B (en) Process for preparing condensed dibenzo-diazepine derivatives
JPH08143565A (ja) ベンズアミド化合物
CN1449386B (zh) 作为血管升压素拮抗剂的非肽取代的螺苯并氮杂*
TW202321232A (zh) 小分子sting拮抗劑
CN101341125B (zh) 作为缓激肽拮抗剂的菲啶衍生物
RS20050638A (sr) Triazolska jedinjenja korisna u terapiji
EP0572235A2 (en) Beta-carboline derivatives with anticholecystoquinine activity

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040228

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000